Plasma solution 수혈 - Plasma solution suhyeol

수액/수혈

Plasma Solution A (플라스마솔루션에이)

상품명- 씨제이 플라스마솔루션에이 주 (Plasma Solution A Inj.)

# 원료약품 및 분량 (1000ml 중)

주성분 : 염화나트륨 5.26g

         글루콘산나트륨 5.02g

         초산나트륨 3.68g

         염화칼륨 0.37g

         염화마그네슘 0.3g

용제 : 주사용수

===> 총 나트륨 3.22g, 총 염소 3.48g, 칼륨 0.19g, 마그네슘 0.036g

# 특장점

1. 중탄산염 (Bicarbonate, HCO3-) 전구체 이용성의 향상으로 혈액 pH를 빨리 정상으로 복귀시킨다

 - 젖산염(Lactate)는 혈류 순환 장애로 인한 간기능 저하시 중탄산염으로 전환이 느려져 과젖산혈증(Hyper-lactaemia)를 유발하는 반면, 씨제이플라스마솔루션에이주의 초산염(Acetate)은 쉽게 분해되어 혈액중의 중탄산염의 급속한 증가와 함께 혈액 pH로 pH를 정상으로 복귀시켜 효과적인 완충제 역할을 수행한다

2. pH가 7.4로 혈액과 동일하다

 - 혈액 및 세포외액과 동일하여 pH변화를 유발하지 않으며, 적혈구 농축액(Packed RBC) 투여시 희석제로써 사용할 수 있다

3. 혈액응고의 위험이 거의 없다

 - Ca++ 이온이 들어있지 않으므로 shock나 외과수술시 혈액응고 유발 위험성이 거의 없으며, 혈액과 동시 투여할 수 있으므로 특히 수술 전후와 수술 중 체액 및 전해질 보급에 효과적이다

4. 간장 및 신장의 부담을 감소시켰다

 - 중탄산염 전구체인 초산염(Acetate)과 글루콘산염(Gluconate)이 거의 완전하게 대사되므로 간에서의 대사부담을 줄였으며, K+이 최소농도로 들어 있으므로 수술중 신장기능에서의 부담이 거의 없다

# 효능, 효과

1. 순환혈액량 및 조직간액의 감소시 세포외액의 보급, 보정

2. 대사성 산증의 보정

# 용법, 용량

보통 성인 1회 500~1000ml를 점적 정맥주사한다

투여속도는 시간당 200ml로 한다

설명서 개정연월일; 2011. 3. 15

• Korean Red Cross. Korean Red Cross blood services statistics 2007. Seoul: Korean Red Cross; 2008.
  
• Korean Red Cross. Korean Red Cross blood services statistics 2011. Seoul: Korean Red Cross; 2012.
  
• Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B. Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012;157:49–58.
  
  
  
• Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012;4:CD002042.
  
  
• Retter A, Wyncoll D, Pearse R, Carson D, McKechnie S, Stanworth S, Allard S, Thomas D, Walsh T. British Committee for Standards in Haematology. Guidelines on the manage-ment of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol 2013;160:445–464.
  
  
  
• Korea Centers for Disease Control and Prevention. 2011 Guidelines for blood transfusion. Cheongwon: Korea Centers for Disease Control and Prevention; 2011.
  
• Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, Moehnle P, Mangano DT;. Investigators of the Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007;116:471–479.
  
  
  
• Choi SH, Seo YH, Ahn JY, Kim KH, Hur HK, Jeon YB, Park PW. Change of the disposal and the cancellation ratio after enforcement of a precedent antibody screening test. Korean J Blood Transfus 2012;23:248–255.
  
  
  
• Ryden SE, Oberman HA. Compatibility of common intravenous solutions with CPD blood. Transfusion 1975;15:250–255.
  
  
  
• Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007;370:415–426.
  
  
  
• American Society of Anesthesiologists Task Force on Periope-rative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology 2006;105:198–208.
  
  
• Kim HO. Guidelines for appropriate and safe transfusion. J Korean Med Assoc 2006;49:391–401.
  
  
  
  
  
• Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007;21:697–729.
  
  
  
• Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001;41:766–770.
  
  
  
• Greeno E, McCullough J, Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion 2007;47:201–205.
  
  
  
• Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Work Group. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009;7:132–150.
  
  
• Murad MH, Stubbs JR, Gandhi MJ, Wang AT, Paul A, Erwin PJ, Montori VM, Roback JD. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion 2010;50:1370–1383.
  
  
  
• Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009;23:177–188.
  
  
  
• Pantanowitz L, Kruskall MS, Uhl L. Cryoprecipitate: patterns of use. Am J Clin Pathol 2003;119:874–881.
  
  
  
• Bassuni WY, Blajchman MA, Al-Moshary MA. Why implement universal leukoreduction? Hematol Oncol Stem Cell Ther 2008;1:106–123.
  
  
  
• Choi SJ, Kim S, Kim HO, Kwon JR, Lee SW, Shin YH. The status of use of leukoreduced blood products in Korean hospitals. Lab Med Online 2012;2:204–208.
  
  
  
  
  
• Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, Saran F, Thurston J, Webb D. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol 2011;152:35–51.
  
  
  
• Couvret C, Tricoche S, Baud A, Dabo B, Buchet S, Palud M, Fusciardi J. The reduction of preoperative autologous blood donation for primary total hip or knee arthroplasty: the effect on subsequent transfusion rates. Anesth Analg 2002;94:815–823.
  
  
  
• McVay PA, Andrews A, Kaplan EB, Black DB, Stehling LC, Strauss RG, Toy PT. Donation reactions among autologous donors. Transfusion 1990;30:249–252.